Novartis Ag

Michael DiDonato

Glen Spraggon

Shelly Meeusen

Christophe Filippi

Yaiza Diaz-De-Durana

Bernhard Hubert Geierstanger

John Trauger

Mark Knuth

Tobias Junt

Carolina Nicole Simpson

Scott Glaser

Jian Shi

Sarah Rue

Christian Cho-Hua Lee

Alexandra Kraus

Anna Galkin

Xenia Karola Wezler

Jonathan Deane

Yong Jia

Klaus Felix Hartlepp

Christoph Erkel

The present disclosure provides for IL2 engrafted into the CDR sequences of an antibody having preferred therapeutic profiles over molecules known and used in the clinic. In particular, the provided antibody cytokine engrafted protein compositions increase or maintain CD8+ T effector cells while reducing the activity of Treg cells. Additionally, provided compositions convey improved half-life, stability and producibility over recombinant human IL2 formulations such as Proleukin®.

Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer

Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies

The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.

Antibody-cytokine engrafted proteins and methods of use for immune related disorders

The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.

Methods of treating immune related disorders using antibody-cytokine engrafted compositions

Antibody cytokine engrafted compositions and methods of use for immunoregulation

Growing community of inventors

San Diego, CA, United States of America

Michael DiDonato